Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

BeiGene announces positive regulatory updates in Europe and the U.S. after recently regaining global rights for Tevimbra (tislelizumab)

Written by | 7 Oct 2023

BeiGene, Ltd. announced that the European Commission (EC) has approved Tevimbra (tislelizumab) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous… read more.

Padcev and Keytruda significantly improve overall survival and progression-free survival in previously untreated advanced bladder cancer in pivotal phase III EV-302 trial – Seagen + Astellas

Written by | 5 Oct 2023

Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EV-302 clinical trial (also known as KEYNOTE-A39) for Padcev (enfortumab vedotin-ejfv) in combination with… read more.

Sexual activity and vaginal dilation associated with fewer side effects after cervical cancer treatment

Written by | 4 Oct 2023

People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study… read more.

Shorter course of radiation therapy is safe for patients with early-stage breast cancer who have undergone mastectomy and reconstruction

Written by | 3 Oct 2023

Researchers at Dana-Farber Brigham Cancer Center have found that a shorter course of radiation therapy after mastectomy and breast reconstruction surgery provides the same protection against breast cancer recurrence and… read more.

How should clinicians prescribe opioids for cancer-related pain in patients who use cocaine or methamphetamines?

Written by | 13 Sep 2023

Clinicians treating cancer-related pain must consider whether and how to prescribe opioids to patients who use nonmedical stimulants such as cocaine and methamphetamines; however, no guidelines exist related… read more.

More cases of breast cancer detected with the help of AI

Written by | 12 Sep 2023

One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet… read more.

Tivdak improved overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy alone – Seagen + Genmab

Written by | 7 Sep 2023

Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line… read more.

Why breast cancer survivors don’t take their medication, and what can be done

Written by | 1 Sep 2023

For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take… read more.

Optimizing tobacco cessation treatment with lung cancer screening

Written by | 29 Aug 2023

Lung cancer is the deadliest cancer in the United States, and 80% of lung cancer deaths are linked to one risk factor: smoking. While lung cancer screenings are… read more.

Good cardiorespiratory fitness associated with up to 40% lower risk of 9 cancers

Written by | 24 Aug 2023

Good cardiorespiratory fitness when young is associated with up to a 40% lower risk of developing 9 specific cancers later on—at least in men—suggests a large long term… read more.

Proton radiotherapy to treat oesophageal cancer

Written by | 19 Aug 2023

A 67-year old patient presenting with oesophageal cancer was treated today at the Paul Scherrer Institute PSI with a form of radiation provided by protons, i.e. positively charged… read more.

FDA approves Talvey a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma – Janssen Pharma

Written by | 15 Aug 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has granted accelerated approval of Talvey (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.